Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naloxegol - AstraZeneca/Nektar Therapeutics

Next Previous
Drug Profile

Naloxegol - AstraZeneca/Nektar Therapeutics

Alternative Names: AZ13337019 oxalate; MOVANTIK; Movantik; Moventig; Naloxegol oxalate; NKTR-118; NKTR-118 oxalate; PEG-naloxol; Pegylated naloxol

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics
  • Developer AstraZeneca; Daiichi Sankyo Company; Knight Therapeutics; Kyowa Kirin International; Nektar Therapeutics; RedHill Biopharma
  • Class Gastrokinetics; Laxatives; Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation

Most Recent Events

  • 02 Aug 2023 Kyowa Kirin enters deal to enter into a joint venture with Grunenthal for Naloxegol (Moventig®) for opioid-induced constipation
  • 27 May 2022 Naloxegol is still in phase I KODIAK16 trial for Constipation in Spain and United Kingdom (PO) (NCT02099591)
  • 23 Sep 2021 RedHill Biopharma, AstraZeneca AB and AstraZeneca Pharmaceuticals LP and Nektar Therapeutics have entered into a settlement and license agreement with Aurobindo Pharma USA, Inc. resolving their patent litigation in the U.S. in response to Aurobindo's ANDA seeking approval by the US FDA .
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top